[...]we note that the creatinine clearance (mean ± standard deviation) in the moderate renal impairment group (defined as creatinine clearance 30-60 mL/min) is reported as 58.7 ± 10.2 mL/min (Table 1), which implies that there were subjects in the moderate renal impairment group whose creatinine clearance was >60 mL/min. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study" Stephan Glund1 Paul Reilly2 Joanne van Ryn3 Joachim Stangier3 This Letter to the Editor refers to the article available at doi:10.1007/ s40262-016-0417-0. [...]there is a dependency of idarucizumab exposure on renal function, and under conditions of more severe renal damage non-renal elimination pathways may have increased relevance. [...]the value for creatinine clearance (CLcr) of volunteers with moderate renal impairment presented in our publication is correct. Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Comment on: "Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-me...

Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study"/Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabig...

10.1007/s40262-016-0481-5